Research progress of fatty acid-binding protein 4 in kidney diseases

doi:10.3877/cma.j.issn.2095-3216.2021.01.009

Abstract

Abstract:

Fatty acid-binding protein 4 (FABP4) plays an important regulatory role in the body′s energy metabolism and inflammatory response, and is closely related to diabetes, obesity, atherosclerosis, and tumors. Considerable studies have confirmed that FABP4 is involved in the pathophysiological process of a variety of kidney diseases, and is expected to become a potential drug target as well as a biomarker for the diagnosis of kidney diseases. This article reviewed the research progress of FABP4 in renal diseases in recent years, combining the research work of the authors′ group.

Key words: Fatty acid-binding protein 4, Kidney disease, Biomarker

Xiaoyan Du, Rongshuang Huang, Liang Ma, Ping Fu. Research progress of fatty acid-binding protein 4 in kidney diseases[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2021, 10(01): 44-46.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2021.01.009

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2021/V10/I01/44

References 27

[1]	Hotamisligil GS, Bernlohr DA. Metabolic functions of FABPs-mechanisms and therapeutic implications [J]. Nat Rev Endocrinol, 2015, 11(10): 592-605.
[2]	Roden M. Blocking fatty acids′ mystery tour: a therapy for metabolic syndrome? [J]. Cell Metabol, 2007, 6(2): 89-91.
[3]	Shi M, Ma L, Fu P. Role of fatty acid binding orotein 4 (FABP4) in kidney disease [J]. Cur Med Chem, 2020, 27(22): 3657-3664.
[4]	Tanaka M, Furuhashi M, Okazaki Y, et al. Ectopic expression of fatty acid-binding protein 4 in the glomerulus is associated with proteinuria and renal dysfunction [J]. Nephron Clin Pract, 2014, 128(3-4): 345-351.
[5]	Elmasri H, Karaaslan C, Teper Y, et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells [J]. FASEB J, 2009, 23(11): 3865-3673.
[6]	Yao F, Li Z, Ehara T, et al. Fatty acid-binding protein 4 mediates apoptosis via endoplasmic reticulum stress in mesangial cells of diabetic nephropathy [J]. Mol Cell Endocrinol, 2015, 411: 232-242.
[7]	Shi M, Huang R, Guo F, et al. Pharmacological inhibition of fatty acid-binding protein 4 (FABP4) protects against renal ischemia-reperfusion injury [J]. RSC Adv, 2018, 8: 15207-15214.
[8]	Huang R, Shi M, Guo F, et al. Pharmacological inhibition of fatty acid-binding protein 4 (FABP4) protects against rhabdomyolysis-induced acute kidney injury [J]. Front Pharmacol, 2018, 9: 917.
[9]	Tan Z, Guo F, Huang Z, et al. Pharmacological and genetic inhibition of fatty acid-binding protein 4 alleviated cisplatin-induced acute kidney injury [J]. J Cell Mol Med, 2019, 23(9): 6260-6270.
[10]	Shi M, Guo F, Liao D, et al. Pharmacological inhibition of fatty acid-binding protein 4 alleviated kidney inflammation and fibrosis in hyperuricemic nephropathy [J]. Eur J Pharmocol, 2020, 887: 173570.
[11]	Feng Y, Guo F, Xia Z, et al. Inhibition of fatty acid-binding protein 4 attenuated kidney fibrosis by mediating macrophage-to-myofibroblast transition [J]. Front Immunol, 2020, 11: 566535.
[12]	Taguchi K, Chen L, Usawachintachit M, et al. Fatty acid-binding protein 4 downregulation drives calcification in the development of kidney stone disease [J]. Kidney Int, 2020, 97(5): 1042-1056.
[13]	Xu A, Wang Y, Xu JY, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome [J]. Clin Chem, 2006, 52(3): 405-413.
[14]	Hao J, Zhang Y, Yan X, et al. Circulating adipose fatty acid binding protein is a new link underlying obesity-associated breast/mammary tumor development [J]. Cell Metabol, 2018, 28(5): 689-705.
[15]	Ebert T, Hopf LM, Wurst U, et al. Circulating adipocyte fatty acid binding protein is increased in chronic and acute renal dysfunction [J]. Nutr Metab Cardiovasc Dis, 2014, 24(9): 1027-1034.
[16]	Fuseya T, Furuhashi M, Yuda S, et al. Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population [J]. Cardiovasc Diabetol, 2014, 13: 126.
[17]	Sommer G, Ziegelmeier M, Bachmann A, et al. Serum levels of adipocyte fatty acid-binding protein (AFABP) are increased in chronic haemodialysis (CD) [J]. Clin Endocrinol, 2008, 69(6): 901-905.
[18]	Toruner F, Altinova A, Akturk M, et al. The relationship between adipocyte fatty acid binding protein-4, retinol binding protein-4 levels and early diabetic nephropathy in patients with type 2 diabetes [J]. Diabetes Res Clin Pract, 2011, 91(2): 203-207.
[19]	Lee C, Cheung CYY, Woo YC, et al. Prospective associations of circulating adipocyte fatty acid-binding protein levels with risks of renal outcomes and mortality in type 2 diabetes [J]. Diabetologia, 2019, 62(1): 169-177.
[20]	Li B, Yang H, Zhang W, et al. Fatty acid-binding protein 4 predicts gestational hypertension and preeclampsia in women with gestational diabetes mellitus [J]. PLoS One, 2018, 13(2): e0192347.
[21]	Okazaki Y, Furuhashi M, Tanaka M, et al. Urinary excretion of fatty acid-binding protein 4 is associated with albuminuria and renal dysfunction [J]. PLoS One, 2014, 9(12): e115429.
[22]	Obajdin J, Cotter M, Snelling S, et al. Fatty-acid binding protein 4 (FABP4) as a potential preclinical biomarker of drug-induced kidney injury [J]. Toxicol Sci, 2018, 166(2): 441-450.
[23]	Furuhashi M, Ishimura S, Ota H, et al. Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease [J]. PLoS One, 2011, 6(11): e27356.
[24]	Bao Y, Lu Z, Zhou M, et al. Serum levels of adipocyte fatty acid-binding protein are associated with the severity of coronary artery disease in Chinese women [J]. PLoS One, 2011, 6(4): e19115.
[25]	Chen Y, Hsu B, Lee C, et al. Serum adipocyte fatty acid-binding protein level is associated with arterial stiffness quantified with cardio-ankle vascular index in kidney transplant patients [J]. Clin Exp Nephrol, 2018, 22(1): 188-195.
[26]	Furuhashi M, Tuncman G, Gorgun C, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2 [J]. Nature, 2007, 447(7147): 959-965.
[27]	Qiao Y, Liu L, Yin L, et al. FABP4 contributes to renal interstitial fibrosis via mediating inflammation and lipid metabolism [J]. Cell Death Dis, 2019, 10(6): 382.

Please choose a citation manager

Content to export